MSR1 and neoplasm: As we can see, the treatment of asialyl-agalactosyl IgG did not change an expression of a general macrophage marker CD68 but increased mRNA and protein levels of tumor-associated macrophage markers CD163 and CD204 in both macrophagic U-937 cells and human peripheral macrophages at day six (Figure 2C,D).